To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 2 Unknown 37 enrolled Sichuan University

NaSingle-groupOpen-labelTreatment

Summary

The Purpose of This Study is to Evaluate the Efficacy and Safety of Cadonilimab（AK104） in Combination With SOX as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.

Timeline

Start: 2023-07
Primary completion: 2025-01
Completion: 2025-07

Publications

Zhang PF, Zhang WH, Liu XJ, He D, Yang K, Gou HF, Hu JK. Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastro-oesophageal junction adenocarcinoma: study protocol for a single-arm, phase II clinical trial. BMJ Open. 2024 Dec 4;14(12):e081529. doi: 10.1136/bmjopen-2023-081529.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cadonilimab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Subject	S-1	Small molecule	40 mg	—
Subject	S-1	Small molecule	60 mg	—

To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Summary

Timeline

Publications

Drugs

Indications